GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Volatility

Alphamab Oncology (HKSE:09966) Volatility : 94.05% (As of May. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-28), Alphamab Oncology's Volatility is 94.05%.


Competitive Comparison of Alphamab Oncology's Volatility

For the Biotechnology subindustry, Alphamab Oncology's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphamab Oncology's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Volatility distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Volatility falls into.



Alphamab Oncology  (HKSE:09966) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alphamab Oncology  (HKSE:09966) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Alphamab Oncology Volatility Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology (HKSE:09966) Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
Executives
South Dakota Trust Company Llc 2301 Trustee
Xu Ting 2305 Beneficiary of a trust
Liu Yang 2307 Founder of a discretionary trust who can infl
Rubymab Ltd. 2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines